{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:14:15Z","timestamp":1759536855586,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1053\/j.ajkd.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T07:38:24Z","timestamp":1568014704000},"page":"579-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cefepime as Empirical Peritoneal Dialysis\u2013Associated Peritonitis Treatment: Something to Dwell On?"],"prefix":"10.1053","volume":"74","author":[{"given":"Muthana","family":"Al Sahlawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Perl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.ajkd.2019.06.008_bib1","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1681\/ASN.2016010112","article-title":"The current state of peritoneal dialysis","volume":"27","author":"Mehrotra","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2019.06.008_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3747\/pdi.2010.00185","article-title":"Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000-2007)","volume":"31","author":"Brown","year":"2011","journal-title":"Perit Dial Int"},{"issue":"1","key":"10.1053\/j.ajkd.2019.06.008_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2215\/CJN.05380518","article-title":"Patient and caregiver priorities for outcomes in peritoneal dialysis: multinational nominal group technique study","volume":"14","author":"Manera","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2019.06.008_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/sdi.12571","article-title":"Innovations in treatment delivery, risk of peritonitis, and patient retention on peritoneal dialysis","volume":"30","author":"Piraino","year":"2017","journal-title":"Semin Dial"},{"issue":"suppl 4","key":"10.1053\/j.ajkd.2019.06.008_bib5","first-page":"S7","article-title":"The incidence of peritoneal dialysis-related infection in Thailand: a nationwide survey","volume":"94","author":"Kanjanabuch","year":"2011","journal-title":"J\u00a0Med Assoc Thailand"},{"issue":"5","key":"10.1053\/j.ajkd.2019.06.008_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3747\/pdi.2016.00078","article-title":"ISPD peritonitis recommendations: 2016 update on prevention and treatment","volume":"36","author":"Li","year":"2016","journal-title":"Perit Dial Int"},{"issue":"5","key":"10.1053\/j.ajkd.2019.06.008_bib7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.ajkd.2019.05.011","article-title":"Intraperitoneal cefepime monotherapy versus combination therapy of cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"74","author":"Kitrungphaiboon","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2019.06.008_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/089686080002000212","article-title":"Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis","volume":"20","author":"Li","year":"2000","journal-title":"Perit Dial Int"},{"issue":"1","key":"10.1053\/j.ajkd.2019.06.008_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/ajkd.2001.25205","article-title":"Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis","volume":"38","author":"Wong","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2019.06.008_bib10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2019.06.008_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/655131","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use","volume":"51","author":"Kim","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2019.06.008_bib12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/ndt\/gfm713","article-title":"The neurotoxicity and safety of treatment with cefepime in patients with renal failure","volume":"23","author":"Sonck","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2019.06.008_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/089686080502500414","article-title":"Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis","volume":"25","author":"Elwell","year":"2005","journal-title":"Perit Dial Int"},{"issue":"9","key":"10.1053\/j.ajkd.2019.06.008_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1345\/aph.18336","article-title":"Stability of cefepime in peritoneal dialysis solution","volume":"33","author":"Williamson","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1053\/j.ajkd.2019.06.008_bib15","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1093\/ndt\/gfr005","article-title":"Antibiotic stability in commercial peritoneal dialysis solutions: influence of formulation, storage and duration","volume":"26","author":"Roberts","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2019.06.008_bib16","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1345\/aph.1E324","article-title":"Stability of cefepime in icodextrin peritoneal dialysis solution","volume":"38","author":"Elwell","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1053\/j.ajkd.2019.06.008_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3747\/pdi.2015.00169","article-title":"Stability of\u00a0cefepime in pH-neutral peritoneal dialysis solutions packaged in dual-compartment bags","volume":"36","author":"Yousaf","year":"2016","journal-title":"Perit Dial Int"},{"issue":"12","key":"10.1053\/j.ajkd.2019.06.008_bib18","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.2215\/CJN.00630117","article-title":"Residual kidney function and peritoneal dialysis-associated peritonitis treatment outcomes","volume":"12","author":"Whitty","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2019.06.008_bib19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1128\/AAC.36.7.1387","article-title":"Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis","volume":"36","author":"Barbhaiya","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1053\/j.ajkd.2019.06.008_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/AAC.00873-13","article-title":"Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis","volume":"58","author":"Cardone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1053\/j.ajkd.2019.06.008_bib21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.V1161117","article-title":"Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients","volume":"11","author":"Low","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2019.06.008_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2009.202","article-title":"Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients","volume":"76","author":"Miles","year":"2009","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2019.06.008_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/089686080702700512","article-title":"Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD","volume":"27","author":"Wong","year":"2007","journal-title":"Perit Dial Int"},{"issue":"7","key":"10.1053\/j.ajkd.2019.06.008_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/1469-0691.12705","article-title":"New epidemiology of Staphylococcus aureus infection in Asia","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Microbiol Infect"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619308820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619308820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:23:02Z","timestamp":1759461782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638619308820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0272638619308820"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.06.008","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cefepime as Empirical Peritoneal Dialysis\u2013Associated Peritonitis Treatment: Something to Dwell On?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.05.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}